Epidemiology and Management of Acute Kidney Injury in Hepatocellular Carcinoma Patients Undergoing Transcatheter Arterial Chemoembolization

Author(s): Chen Xiao Hong, Lv Wen Lv, Liu Zhong Hua, Shen Bo, Cao Xue Sen, Nie Yu Xin, Yu Jia Wei, Xu Jia Rui, Ding Xiao Qiang, Zou Jian Zhou*

Journal Name: Current Protein & Peptide Science

Volume 18 , Issue 12 , 2017

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Transcatheter arterial chemoembolization (TACE) is an effective therapy for hepatocellular carcinoma (HCC). However, acute kidney injury (AKI) may occur after TACE due to the contrast agent and cytotoxic anticancer drugs used in this procedure. Post-TACE AKI is not an unusual event, and may adversely affect patient outcome. Coexisting situations including cirrhosis, renal insufficiency, diabetes and hypertension play a role in the development of HCC, and may predispose patients to AKI after TACE. Most post-TACE are transient and reversible, while prolonged AKI may predict a decreased survival. The best strategy to manage post-TACE AKI is prevention. Patients, before undergoing TACE, should be carefully assessed. In this study, we reviewed the current literature published in English about the incidence rate, risk factors, management and prognosis of AKI in patients with HCC undergoing TACE for a better understanding of this complication.

Keywords: Acute kidney injury, transcatheter arterial chemoembolization, incidence, risk factor, prognosis, prevention.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 08 October, 2017
Page: [1218 - 1223]
Pages: 6
DOI: 10.2174/1389203717666160909124305
Price: $65

Article Metrics

PDF: 38